Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Amylyx Pharmaceuticals, Inc. - Common Stock (NQ:AMLX)

13.94 +0.74 (+5.61%)
Streaming Delayed Price Updated: 1:57 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Amylyx Pharmaceuticals, Inc. - Common Stock

< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Receives Negative CHMP Opinion on its Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union Following Re-Examination Process
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
2 Incredible Growth Stocks Near 52-Week Lows to Buy Now ↗
These two high-tech bio companies may be too cheap to ignore right now. 
Via The Motley Fool
News headline image
Amylyx Pharmaceuticals Announces Publication of Survival Analysis Comparing CENTAUR to Historical Clinical Trial Control
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Provides Update on Accès Compassionnel for AMX0035 in France
From Amylyx Pharmaceuticals
Via Business Wire
News headline image
RELYVRIO® and AMX0114 Data to be Presented at 22nd Annual Northeast ALS Consortium (NEALS) Meeting
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Expert Ratings for Amylyx Pharma ↗
 
Via Benzinga
News headline image
A Preview Of Amylyx Pharma's Earnings ↗
 
Via Benzinga
News headline image
Why Shares of Amylyx Pharmaceuticals Were Up Monday ↗
The company got a bump from an analyst's upgrade. 
Via The Motley Fool
News headline image
3 Up-and-Coming Biotech Stocks to Put on Your Must-Buy List ↗
Here are some intriguing up-and-coming biotech stocks that may reward risk-tolerant investors with a long-term outlook. 
Via InvestorPlace
News headline image
Amylyx Pharmaceuticals Reports Second Quarter 2023 Financial Results
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals to Report Second Quarter 2023 Financial Results on August 10, 2023
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
3 Biotech Stocks to Buy Before Drug Trials End ↗
Drug trials are a chance for high risk, high reward investing. These stocks doing neurodegenerative trials could be set for big gains. 
Via InvestorPlace
News headline image
4 Analysts Have This to Say About Amylyx Pharma ↗
 
Via Benzinga
News headline image
7 Analysts Have This to Say About Amylyx Pharma ↗
 
Via Benzinga
News headline image
What 7 Analyst Ratings Have To Say About Amylyx Pharma ↗
 
Via Benzinga
News headline image
Amylyx Stock Has A Good Entry Point, Says Bullish Goldman Sachs ↗
Shares of Amylyx Pharmaceuticals Inc (NASDAQ: AMLX) jumped in early trading on Monday, after remaining broadly flat last week. 
Via Benzinga
News headline image
Benzinga's Top Ratings Upgrades, Downgrades For July 24, 2023 ↗
 
Via Benzinga
News headline image
Amylyx Pharmaceuticals to Host Virtual Webcast on AMX0035 Progressive Supranuclear Palsy (PSP) Program
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Analyst Expectations for Amylyx Pharma's Future ↗
 
Via Benzinga
News headline image
EMA's Advisory Panel Gives Thumbs Down To Amylyx Pharma's Amyotrophic Lateral Sclerosis Treatment ↗
The European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a negative opinion regarding Amylyx Pharmaceuticals Inc's (NASDAQ: AMLX) conditional marketing authorization... 
Via Benzinga
News headline image
Amylyx Pharmaceuticals Receives CHMP Negative Opinion on its Conditional Marketing Authorisation Application for AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Completes Negotiation Process and Signs Letter of Intent with the pCPA for ALBRIOZA™ for the Treatment of ALS
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Better Growth Stock: Amylyx Pharmaceuticals or Viking Therapeutics? ↗
Which of these red-hot biotech stocks is the better buy right now? 
Via The Motley Fool
News headline image
Amylyx Pharmaceuticals to Present at the Goldman Sachs 44th Annual Global Healthcare Conference
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run ↗
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
News headline image
Amylyx Pharmaceuticals Provides Update on Ongoing Regulatory Review of AMX0035 for the Treatment of ALS in the European Union
From Amylyx Pharmaceuticals, Inc.
Via Business Wire
News headline image
Amylyx Pharmaceuticals Turns Profitable On Successful Drug Launch
Amylyx Pharmaceuticals is the rare young biotech that's profitable. The company earned $0.02 a share in Q1, and analysts expect profitability to grow. 
Via MarketBeat
News headline image
2 Supercharged Growth Stocks to Buy Right Now ↗
These two biopharma stocks might be poised for a major breakout. 
Via The Motley Fool
< Previous 1 2
...
10 11 12 13 14 15 16 17 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.